Genetic Polymorphic Impact of Metabolizing Enzyme (CYP3A4 and UGT1A4 genes) on Anastrazole Response in Iraqi Breast Cancer Women
1. Abstract 1.1. Background and Objective: Anastrazole is an aromatase inhibitor used widely in therapy of breast cancer and has been metabolized by CYP3A4 and UGT1A4 in liver. Breast cancer is the most common cancer type in worldwide and the second causes of death after lung cancer and the one of therapy that use in its treatment is aromatase inhibiter, anastrazole has been indicated CYP3A1 and UGT1A4 are the main metabolizing enzyme, so the interindividual variation in anastrazole response are due to polymorphism of these gene. We have aimed to determine whether CYP3A4*22 and UGT1A4*2 single nucleotide polymorphisms can have affected on the response of anastrazole.